{"article_title": "Pharmaceutical Companies Buy Rivals\u2019 Drugs, Then Jack Up the Prices", "article_keywords": ["shifted", "pharmaceutical", "plant", "buy", "rights", "drugs", "rose", "valeant", "work", "companies", "rivals", "testing", "jack", "prices", "result"], "article_url": "http://www.wsj.com/articles/pharmaceutical-companies-buy-rivals-drugs-then-jack-up-the-prices-1430096431", "article_text": "On Feb. 10, Valeant Pharmaceuticals International Inc. bought the rights to a pair of life-saving heart drugs. The same day, their list prices rose by 525% and 212%.\n\nNeither of the drugs, Nitropress or Isuprel, was improved as a result of costly investment in lab work and human testing, Valeant said. Nor was manufacture of the medicines shifted to an expensive new plant. The big change: the drugs\u2019 ownership.\n\n\u201cOur duty is to...", "article_metadata": {"article.template": "snippet", "article.created": "2015-04-27T01:00:00.000Z", "article.section": "Business", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "List prices soar on Valeant\u2019s heart medications and other firm\u2019s drugs, driving up costs.", "creator": "@jonathanrockoff", "image": {"alt": "Pharmaceutical companies buy rivals\u2019 drugs, then jack up the prices", "identifier": "https://si.wsj.net/public/resources/images/OG-AE282_201504_D_20150426183252.jpg"}, "title": "Pharmaceutical Companies Buy Rivals\u2019 Drugs, Then Jack Up the Prices", "site": "@WSJ", "card": "summary_large_image"}, "al": {"ios": {"url": "wsj://launch?articleid=SB11743384491554794345504580556210151257320&headline=Pharmaceutical%20companies%20buy%20rivals%u2019%20drugs%2C%20then%20jack%20up%20the%20prices&weburl=http://www.wsj.com/articles/SB11743384491554794345504580556210151257320"}}, "page.site.product": "WSJ", "keywords": "drug industry deals,drug makers,drug price increases,drug prices,pharmaceutical industry,Valeant Pharmaceuticals International,VRX,Truven Health Analytics,IMS Health Holdings,IMS,Express Scripts Holding,ESRX,AstraZeneca,AZN,AZN.LN,marketing,markets,pricing,corporate,industrial news,health,pharmaceuticals,health care,life sciences", "news_keywords": "drug industry deals,drug makers,drug price increases,drug prices,pharmaceutical industry,Valeant Pharmaceuticals International,VRX,Truven Health Analytics,IMS Health Holdings,IMS", "article.headline": "Pharmaceutical companies buy rivals\u2019 drugs, then jack up the prices", "cXenseParse": {"candybar": {"image": "https://si.wsj.net/public/resources/images/OG-AE282_201504_E_20150426183252.jpg"}, "poptart": {"image": "https://si.wsj.net/public/resources/images/OG-AE282_201504_D_20150426183252.jpg"}}, "description": "List prices soar on Valeant\u2019s heart medications and other firm\u2019s drugs, driving up costs.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB11743384491554794345504580556210151257320&headline=Pharmaceutical%20companies%20buy%20rivals%u2019%20drugs%2C%20then%20jack%20up%20the%20prices&weburl=http://www.wsj.com/articles/SB11743384491554794345504580556210151257320", "user.type": "nonsubscriber", "article.page": "Health Care", "article.emb": "video_emb", "page.content.format": "responsive", "article.summary": "List prices soar on Valeant\u2019s heart medications and other firm\u2019s drugs, driving up costs.", "page.site": "wsj", "testkeys": "C", "article.published": "2015-04-27T01:00:00.000Z", "dj.asn": "i-43d5", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"internal_link_count": 2, "video_count": 1, "image_count": 2, "word_count": 1409, "publisher": "https://www.facebook.com/wsj"}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "List prices soar on Valeant\u2019s heart medications and other firm\u2019s drugs, driving up costs.", "title": "Pharmaceutical Companies Buy Rivals\u2019 Drugs, Then Jack Up the Prices", "url": "http://www.wsj.com/articles/pharmaceutical-companies-buy-rivals-drugs-then-jack-up-the-prices-1430096431", "image": {"width": 359, "identifier": "https://si.wsj.net/public/resources/images/OG-AE282_201504_E_20150426183252.jpg", "height": 239}, "locale": "en_US", "type": "article"}, "author": "Jonathan D. Rockoff and Ed Silverman", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Pharmaceutical Companies Buy Rival\u2019s Drugs, Then Jack Up the Prices", "article.type": "Health", "article.id": "SB11743384491554794345504580556210151257320", "user.exp": "default", "article.updated": "2015-04-27T01:00:00.000Z"}, "_id": "\"57477af46914bd0286fd756e\"", "article_summary": "The same day, their list prices rose by 525% and 212%.\nNeither of the drugs, Nitropress or Isuprel, was improved as a result of costly investment in lab work and human testing, Valeant said.\nOn Feb. 10, Valeant Pharmaceuticals International Inc. bought the rights to a pair of life-saving heart drugs.\nNor was manufacture of the medicines shifted to an expensive new plant.\nThe big change: the drugs\u2019 ownership."}